User:Mr. Ibrahem/Ticagrelor
Clinical data | |
---|---|
Trade names | Brilinta, Brilique, others |
Other names | AZD-6140 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611050 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Adenosine diphosphate receptor inhibitor[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 36% |
Protein binding | >99.7% |
Metabolism | Liver (CYP3A4) |
Elimination half-life | 7 hrs (ticagrelor), 8.5 hrs (active metabolite AR-C124910XX) |
Excretion | Bile duct |
Identifiers | |
| |
Chemical and physical data | |
Formula | C23H28F2N6O4S |
Molar mass | 522.57 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Ticagrelor, sold under the brand name Brilinta among others, is a medication used in acute coronary syndrome to prevent stroke and heart attacks.[2][3] It is generally used with aspirin.[2] It is taken by mouth.[2]
Common side effects include bleeding and shortness of breath.[2] Other side effects may include cough, diarrhea, and low blood pressure.[3] It is a platelet aggregation inhibitor, specifically a adenosine diphosphate receptor inhibitor, which works by blocking ADP from attaching to platelets.[2][1]
Ticagrelor was approved for medical use in Europe 2010,[2] and in the United States in 2011.[3] In the United Kingdom 4 weeks of medication costs the NHS about £55 as of 2021.[1] In the United States this amount costs about 380 USD as of 2021.[4]
References[edit]
- ^ a b c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 229. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link) - ^ a b c d e f g h "Brilique". Archived from the original on 2 May 2021. Retrieved 3 October 2021.
- ^ a b c d "Ticagrelor Monograph for Professionals". Drugs.com. Archived from the original on 17 September 2020. Retrieved 3 October 2021.
- ^ "Brilinta Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 5 November 2016. Retrieved 3 October 2021.